Expression Genetics, Inc.'s EGEN-001 Named One of 10 Most Promising Oncology Products
9/5/2008 10:59:03 AM
More...
|
Expression Genetics, Inc. Raises $12 Million
8/5/2008 8:08:15 AM
More...
|
Expression Genetics, Inc. Specializing in DNA/RNAi Delivery and Therapeutics, Completes $12M Series B Financing
8/4/2008 6:13:49 AM
More...
|
Expression Genetics, Inc. Announces Further Clinical Advancement of its Gene-Based IL-12 Therapy Co-administered with Standard Chemotherapy for Treatment of Ovarian Cancer
7/20/2007 10:38:22 AM
More...
|
Expression Genetics, Inc. Receives Orphan Drug Grant from FDA for Clinical Development of EGEN-001 for Treatment of Ovarian Cancer
5/3/2007 9:20:46 AM
More...
|
Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
4/16/2007 1:20:20 PM
More...
|
Expression Genetics, Inc. Announces EGEN-001 Cancer Therapeutic Has Been Included In The Top 100 Great Investigational Drug List
4/28/2006 10:54:22 AM
More...
|
Expression Genetics, Inc. Announces Enrollment Of First Patients In Phase I Clinical Trial Of Gene-Based IL-12 For Treatment Of Ovarian Cancer
10/19/2005 5:13:22 PM
More...
|